CEimpact Podcast
The CEimpact Podcast features three shows; GameChangers, Precept2Practice, and LevelUp.
The GameChangers podcast, hosted by Geoff Wall, features the latest game-changing pharmacotherapy advances impacting patient care. New episodes arrive every Monday, and users can earn CPE from each episode.
The Precept2Practice podcast, hosted by Kathy Scott, features information and resources you can use to precept students and residents. New episodes arrive on the third Wednesday of every month. CEimpact CE Plan members can earn CPE for each episode.
To support our shows, give us a follow and check back each week for our latest episodes.
CEimpact Podcast
Dupilumab in COPD
A new biologic agent, Dupilimab, may be a possible treatment for chronic obstructive pulmonary disorder. Join host, Geoff Wall, as he evaluates the use of dupilimab in COPD with Type 2 inflammation
The GameChanger
Type 2 inflammation is driven by eosinophils and IL-4, 5, and 11. It occurs in 20% of patients with COPD. Dupilimab was able to decrease COPD exacerbations by 50% and improve symptoms
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21. PMID: 37272521.
https://www.nejm.org/doi/full/10.1056/NEJMoa2303951
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the different phenotypes of COPD and treatment options
2. Describe the BOREAS trial and the applicability to patients with COPD
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-288-H01-P
Initial release date: 8/21/2023
Expiration date: 8/21/2024
Additional CPE details can be found here.